PFE Jan 2025 50.000 call
| Previous close | 0.0300 |
| Open | 0.0200 |
| Bid | 0.0200 |
| Ask | 0.0300 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0200 - 0.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | 19.08k |
Investor's Business DailyNovavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
Business WireU.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
NEW YORK, October 11, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors.
Investor's Business DailyIs Pfizer Stock A Sell Following The First Salvo In Its Battle With Starboard?
Is Pfizer stock a sell after activist investor Starboard Value reportedly took a $1 billion stake in the drugmaker? Is PFE stock a sell?
